샘플 요청 목록

 카트 문의
시장보고서
상품코드
1796077

세계의 진해제 시장

Antitussive Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 372 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

진해제 세계 시장은 2030년까지 19억 달러에 달할 전망

2024년에 15억 달러로 추정되는 진해제 세계 시장은 2024-2030년 분석 기간 동안 CAGR 3.6%로 성장하여 2030년에는 19억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 말초 작용제는 CAGR 3.9%를 기록하며 분석 기간 종료까지 11억 달러에 달할 것으로 예상됩니다. 중추 작용제 부문의 성장률은 분석 기간 동안 CAGR 2.6%로 추정됩니다.

미국 시장은 4억 1,630만 달러로 추정, 중국은 CAGR 6.7%로 성장 예측

미국의 진해제 시장은 2024년에 4억 1,630만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 6.7%로 2030년까지 3억 7,780만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.4%와 2.8%로 예측됩니다. 유럽에서는 독일이 CAGR 2.0%로 성장할 것으로 예측됩니다.

세계의 진해제 시장 - 주요 동향과 촉진요인 정리

왜 진해제가 호흡기 건강 관리의 중심이 되는가?

일반적으로 기침약으로 알려진 진해제는 기침이 지속되거나 기침이 멈추지 않는 호흡기질환의 관리에 필수적인 요소로 자리 잡았습니다. 이러한 약제는 급성 상기도 감염, 만성 기관지염, 천식 관련 기침, 일부 폐섬유증 및 폐암 등 기침이 환자의 편안함과 삶의 질에 큰 영향을 미치는 질환에 특히 효과적입니다. 진해제는 뇌의 기침 중추에 작용하거나 염증을 일으킨 기도를 진정시켜 기침의 빈도와 강도를 줄여줍니다. 이 약들은 일반적으로 중추에 작용하는 약과 말초에 작용하는 약으로 나뉩니다. 코데인이나 덱스트로메토르판과 같은 중추신경계 약물은 뇌간 수준에서 기침 반사를 억제하는 반면, 말초신경계 약물은 감각신경과 기도 염증을 표적으로 삼습니다. 공해, 흡연, 계절성 바이러스, 만성질환 등으로 인해 전 세계적으로 호흡기질환이 지속적으로 증가함에 따라 진해제를 통한 효과적인 증상 완화에 대한 수요가 증가하고 있습니다. 또한, 즉각적인 증상 완화를 원하는 환자들의 선호와 시중에서 쉽게 구할 수 있다는 점 때문에 처방약과 비처방약 모두 처방약과 비처방약 모두 상비약으로 자리 잡게 되었습니다. 소아과나 노인의학에서는 지속적인 기침이 수면과 영양 섭취를 방해할 수 있기 때문에 이 약들은 중요한 완화제가 되기도 합니다. 진해제는 연령대나 질환에 관계없이 광범위하게 사용되고 있어 호흡기 치료의 최전선에 있는 도구로서 전 세계적으로 중요한 역할을 하고 있음을 알 수 있습니다.

기술 혁신은 진해제 처방과 투여에 어떤 영향을 미치고 있는가?

진해제 분야의 기술 혁신은 이러한 약물이 제형화, 전달 및 의약품으로 널리 인식되는 방식을 재정의하고 있습니다. 기존의 제제는 시럽이나 정제 형태인 경우가 많았지만, 현재는 서방형 캡슐, 용해성 스트립, 비강 스프레이, 마름모꼴 등 첨단 전달 시스템으로 보완되어 보다 빠른 작용 발현과 지속적인 증상 완화를 실현하고 있습니다. 이러한 기술 혁신은 특히 표준 경구용 약물을 복용하기 어려운 소아 및 노인 환자들의 복약 순응도를 향상시키는 것을 목표로 하고 있습니다. 제약사들은 또한 기침 반사에 관여하는 특정 신경 수용체를 표적으로 삼는 새로운 활성 화합물에 투자하여 코데인과 같은 오피오이드계 진해제에서 흔히 나타나는 졸음, 변비, 잠재적 의존성 등의 부작용을 최소화하고 있습니다. ATP 민감성 칼륨 채널이나 TRPV1, P2X3와 같은 감각 뉴런 표적을 조절하는 약물과 같은 비오피오이드 계열의 대체 약물이 임상시험에서 유망한 것으로 나타났습니다. 이들 신약 중 일부는 효과적인 표준치료제가 없는 난치성 만성 기침에 특화되어 개발되고 있습니다. 또한, 약동학의 발전으로 보다 정확한 투여 요법이 가능해졌고, 향료 마스킹 기술을 통해 특히 소아용 제제의 기호성이 개선되고 있습니다. 생명공학 또한 신경기능을 손상시키지 않으면서 기도 과민성을 감소시키는 식물성 화합물이나 면역조절 화합물을 찾아내는데 기여하고 있습니다. 이러한 지속적인 기술 혁신을 통해 진해 치료는 더 많은 환자들에게 더 안전하고, 더 안전하고, 더 많은 환자들이 이용할 수 있는 치료법이 되고 있습니다. 정밀의료와 환자 중심의 의약품 개발이 계속 발전하고 있는 가운데, 진해제는 단순한 대증요법이 아닌 호흡기 치료에 대한 보다 섬세하고 개별화된 접근법의 일부로 자리매김하고 있습니다.

규제 정책, 소비자 동향, 시장 세분화는 진해제 수요를 어떻게 형성하고 있는가?

진해제에 대한 수요는 규제 프레임워크, 소비자 선호도 변화, 의약품 시장 세분화에 따라 크게 형성됩니다. FDA, EMA, 각국 보건기관 등 규제기관은 특히 유효성분에 코데인과 같은 규제 물질이 포함된 경우, 어떤 제제가 일반의약품으로 판매될 수 있는지, 어떤 제제가 처방전이 필요한지 결정하는 데 중요한 역할을 합니다. 최근 오피오이드 의존성 및 오남용에 대한 우려로 인해 코데인 함유 진해제에 대한 규제가 강화되어 보다 안전한 비오피오이드 대체 약물로의 전환이 촉진되고 있습니다. 이를 통해 제조업체는 제품을 개선하고 효능과 안전성 기준을 모두 충족하는 혁신적인 화합물을 개발할 수 있는 새로운 기회를 얻게 되었습니다. 한편, 소비자 행동도 시장에 영향을 미치고 있으며, 졸음을 유발하지 않는 천연 또는 허브 기반 치료제를 찾는 환자가 증가하고 있습니다. 이러한 추세는 보다 광범위한 건강보조식품 및 건강 산업에서 진해제 분야의 확장을 촉진하고 있으며, 꿀, 담쟁이 잎 추출물, 생강 등의 성분을 함유한 제품이 인기를 끌고 있습니다. 또한, 계절 및 전염병 관련 요인에 따라 수요 패턴이 변화하며, COVID-19 사태에서 볼 수 있듯이 감기나 독감 시즌이나 호흡기 바이러스가 유행할 때 매출이 급증하는 것을 볼 수 있습니다. 약국, E-Commerce 플랫폼, 소비자 직접 판매 채널은 모두 재고 및 물류 역량을 강화하여 이러한 변동에 적응하고 있습니다. 시장 세분화 관점에서 볼 때, 소아 및 노인 인구는 연령에 맞는 제형과 투여 지침이 필요하며, 만성질환 환자는 보다 전문적인 개입이 필요합니다. 이러한 다층적이고 역동적인 시장 환경은 제약사들이 경쟁력과 관련성을 유지하기 위해 다양한 제품 포트폴리오를 개발하고, 규제 기준에 부합하며, 변화하는 소비자 기대에 부응할 것을 요구하고 있습니다.

진해거담제 시장의 세계 확대 원동력은?

진해제 시장의 성장은 호흡기질환의 유병률 증가, 고령화 인구 증가, 오염 수준 증가, 전 세계 일반의약품의 접근성 등 여러 가지 요인이 복합적으로 작용하여 성장하고 있습니다. 가장 강력한 촉진요인 중 하나는 천식, 만성 기관지염, COPD와 같은 만성 호흡기질환의 발생률 증가이며, 이들은 모두 만성 또는 재발성 기침을 동반하는 경우가 많습니다. 이와 함께 독감, RSV, 감기 등 급성 감염성 질환이 유행하면서 계절적으로 빠른 효과가 있는 기침약에 대한 수요가 급증하고 있습니다. 특히 신흥시장의 도시화와 산업화는 대기오염과 호흡기 과민증을 조장하여 대증요법의 필요성을 더욱 높이고 있습니다. 노인은 면역력 저하와 건강 상태의 동반으로 인해 호흡기 증상의 빈도와 중증도가 높아지는 경향이 있기 때문에 세계 인구의 고령화도 큰 역할을 하고 있습니다. 진해거담제는 시판되고 있으며, 유통 경로도 널리 보급되어 있어 소비자는 즉시 의료기관을 방문하지 않고도 증상을 자가 관리할 수 있습니다. 제약사들은 전략적 마케팅, 제품 라인업 확대, 지역별 제품 커스터마이징을 통해 이러한 접근성을 활용하고 있습니다. 연구개발에 대한 지속적인 투자는 특히 만성 기침 및 치료 저항성 기침 환자들에게 치료 옵션을 넓혀주고 있습니다. 공중보건 인식 개선 캠페인과 원격의료 플랫폼은 조기 증상 관리를 촉진하고, 결과적으로 약물 복용을 증가시키고 있습니다. 호흡기 건강이 전 세계 건강 문제, 특히 바이러스 유행 이후 호흡기 건강에 대한 관심이 높아짐에 따라, 진해제 시장은 임상적 필요성과 소비자 주도의 완화 수요에 힘입어 꾸준하고 지속적인 성장을 보일 것으로 예상됩니다.

부문

약물 종류별(말초에 작용하는 약제, 중추에 작용하는 약제, 기타 약물 종류), 제형별(정제, 시럽제, 기타 제형), 적응증별(통증, 감기, 기침, 기타 적응증)

조사 대상 기업 사례

  • Alkem Laboratories
  • Alembic Pharmaceuticals
  • Amneal Pharmaceuticals
  • Aurobindo Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla
  • F. Hoffmann-La Roche
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co.
  • Mylan(Viatris)
  • Novartis
  • Pfizer
  • Sanofi
  • Taisho Pharmaceutical
  • Teva Pharmaceutical Industries

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.02

Global Antitussive Drugs Market to Reach US$1.9 Billion by 2030

The global market for Antitussive Drugs estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Peripherally Acting Drugs, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Centrally Acting Drugs segment is estimated at 2.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$416.3 Million While China is Forecast to Grow at 6.7% CAGR

The Antitussive Drugs market in the U.S. is estimated at US$416.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$377.8 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Antitussive Drugs Market - Key Trends & Drivers Summarized

Why Are Antitussive Drugs Central to Respiratory Healthcare Management?

Antitussive drugs, commonly known as cough suppressants, have become essential components in the management of respiratory ailments that feature persistent or disruptive coughing as a primary symptom. These medications are particularly relevant for conditions such as acute upper respiratory tract infections, chronic bronchitis, asthma-related coughing, and certain forms of pulmonary fibrosis or lung cancer, where cough significantly affects patient comfort and quality of life. By acting on the cough center in the brain or soothing the irritated airways, antitussive drugs help reduce the frequency and intensity of coughing, which can be physically exhausting, socially disruptive, and even harmful in cases of severe or prolonged episodes. These medications are generally classified into centrally acting and peripherally acting agents. Centrally acting drugs like codeine and dextromethorphan suppress the cough reflex at the level of the brainstem, whereas peripherally acting drugs target the sensory nerves or airway inflammation. As respiratory illnesses continue to rise globally due to pollution, smoking, seasonal viruses, and chronic conditions, the demand for effective symptomatic relief through antitussive therapy is increasing. Additionally, patient preferences for immediate symptom control and over-the-counter accessibility have further popularized these drugs, making them a regular feature in both prescription and non-prescription medicine cabinets. In pediatric and geriatric care, where persistent coughing can interfere with sleep and nutrition, these drugs also offer critical relief. The widespread application of antitussives across age groups and clinical conditions underlines their significance as a frontline tool in respiratory care management worldwide.

How Is Innovation Influencing the Formulation and Delivery of Antitussive Medications?

Innovation in the field of antitussive drugs is redefining how these medications are formulated, delivered, and perceived in the broader pharmaceutical landscape. Traditional formulations, often in the form of syrups and tablets, are now being complemented by advanced delivery systems such as extended-release capsules, dissolvable strips, nasal sprays, and lozenges that provide faster onset of action or sustained symptom relief. These innovations aim to improve patient compliance, particularly among children and elderly individuals who may struggle with standard oral medications. Pharmaceutical companies are also investing in novel active compounds that target specific neural receptors involved in the cough reflex, minimizing side effects such as drowsiness, constipation, or potential dependency that are commonly associated with opioid-based antitussives like codeine. Non-opioid alternatives, including agents that modulate ATP-sensitive potassium channels or sensory neuron targets like TRPV1 and P2X3, are showing promise in clinical trials. Some of these emerging drugs are being developed specifically for refractory chronic cough, a condition that lacks effective standard treatment. Additionally, advances in pharmacokinetics are enabling more precise dosing regimens, while flavor-masking technologies are improving palatability, especially in pediatric formulations. Biotechnology is also contributing by exploring plant-based and immunomodulatory compounds that reduce airway sensitivity without impairing neurological function. These ongoing innovations are making antitussive therapy more targeted, safer, and accessible to a broader patient population. As precision medicine and patient-centric drug development continue to evolve, antitussive drugs are being positioned not just as symptomatic relief tools but as part of a more nuanced and individualized approach to respiratory treatment.

How Do Regulatory Policies, Consumer Trends, and Market Segmentation Shape the Demand for Antitussives?

The demand for antitussive drugs is significantly shaped by regulatory frameworks, evolving consumer preferences, and the segmentation of the pharmaceutical market. Regulatory bodies like the FDA, EMA, and national health agencies play a critical role in determining which formulations can be sold over-the-counter and which require prescriptions, especially when active ingredients involve controlled substances such as codeine. In recent years, concerns about opioid dependency and misuse have led to tighter regulations around codeine-containing cough suppressants, prompting a shift toward safer, non-opioid alternatives. This has opened new opportunities for manufacturers to reformulate products and develop innovative compounds that meet both efficacy and safety benchmarks. Meanwhile, consumer behavior is influencing the market as patients increasingly seek non-drowsy, natural, or herbal-based remedies. This trend has fueled the expansion of the antitussive segment within the broader nutraceutical and wellness industry, with products incorporating ingredients like honey, ivy leaf extract, or ginger gaining popularity. Additionally, seasonal and pandemic-related factors have altered demand patterns, with spikes in sales during cold and flu seasons or respiratory virus outbreaks, as seen during the COVID-19 pandemic. Pharmacies, e-commerce platforms, and direct-to-consumer channels are all adapting to this variability by enhancing their inventory and logistics capabilities. In terms of market segmentation, the pediatric and geriatric populations require age-specific formulations and dosing guidelines, while patients with chronic conditions demand more specialized interventions. This layered and dynamic market environment encourages pharmaceutical companies to develop diverse product portfolios, align with regulatory standards, and respond to shifting consumer expectations in order to remain competitive and relevant.

What Is Fueling the Global Expansion of the Antitussive Drugs Market?

The growth in the antitussive drugs market is driven by several intersecting factors, including the rising prevalence of respiratory illnesses, expanding aging populations, increasing pollution levels, and the global accessibility of over-the-counter medication. One of the most powerful growth drivers is the increasing incidence of chronic respiratory diseases such as asthma, chronic bronchitis, and COPD, all of which often involve chronic or recurrent coughing. In parallel, the spread of acute infections like influenza, RSV, and the common cold continues to generate seasonal demand spikes for fast-acting cough relief. Urbanization and industrialization, particularly in emerging markets, are contributing to air pollution and respiratory hypersensitivity, further amplifying the need for symptomatic treatments. The aging global population also plays a significant role, as older adults tend to experience more frequent and severe respiratory symptoms due to weakened immunity and coexisting health conditions. Over-the-counter availability and widespread distribution channels make antitussive medications easily accessible, allowing consumers to self-manage their symptoms without immediate medical consultation. Pharmaceutical companies are leveraging this accessibility through strategic marketing, broadening product ranges, and regional product customization. Continued investment in research and development is also expanding therapeutic options, particularly for patients with chronic or treatment-resistant coughs. Public health awareness campaigns and telemedicine platforms are encouraging earlier symptom management, which in turn increases medication uptake. As respiratory wellness becomes an increasing focus in global health discussions, especially in the aftermath of viral pandemics, the antitussive drug market is expected to see steady and sustained growth, underpinned by both clinical necessity and consumer-driven demand for relief.

SCOPE OF STUDY:

The report analyzes the Antitussive Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Peripherally Acting Drugs, Centrally Acting Drugs, Other Drug Classes); Form (Tablets Form, Syrup Form, Other Forms); Indication (Pain Indication, Cold Indication, Cough Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Alkem Laboratories
  • Alembic Pharmaceuticals
  • Amneal Pharmaceuticals
  • Aurobindo Pharma
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Cipla
  • F. Hoffmann-La Roche
  • Glenmark Pharmaceuticals
  • Hikma Pharmaceuticals
  • Intas Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co.
  • Mylan (Viatris)
  • Novartis
  • Pfizer
  • Sanofi
  • Taisho Pharmaceutical
  • Teva Pharmaceutical Industries

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Antitussive Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Respiratory Infections and Allergies Spurs Demand for Over-the-Counter and Prescription Antitussives
    • Here's How Post-Viral Cough Syndromes, Including Long COVID, Strengthen the Business Case for Extended-Use Cough Suppressants
    • Seasonal Influenza and RSV Surges Throw the Spotlight on Rapid-Acting, Broad-Spectrum Antitussive Therapies
    • Growing Preference for Symptomatic Relief Drives Continued Use of OTC Cough Suppressants in Self-Medication Markets
    • Expansion of Geriatric and Pediatric Populations Sustains Demand for Age-Appropriate, Formulation-Specific Antitussive Drugs
    • Here's the Story: Consumer Shift Toward Natural and Herbal-Based Remedies Unlocks Growth for Plant-Derived Antitussives
    • Concerns Over Opioid Misuse and Abuse Spur Regulatory Scrutiny and Reformulation of Codeine-Based Antitussives
    • Research in Non-Opioid Mechanisms of Action Encourages Innovation in Central and Peripheral Cough Modulators
    • Here's How E-Commerce and Digital Pharmacies Expand Access to Branded and Generic Cough Formulations Across Emerging Markets
    • Combination Therapies for Cold and Cough Drive Market for Multi-Symptom Relief Medications with Antitussive Components
    • Rising Focus on Chronic Cough and Refractory Cough Conditions Supports Development of Specialized Prescription Therapies
    • Here's How Consumer Demand for Fast Relief and Palatable Formulations Fuels Innovation in Lozenges, Syrups, and Rapid-Dissolve Formats
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antitussive Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antitussive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Peripherally Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Peripherally Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Peripherally Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Centrally Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Centrally Acting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Centrally Acting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pain Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pain Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Pain Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cold Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cold Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Cold Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Cough Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Cough Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Cough Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Tablets Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Tablets Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Tablets Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Syrup Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Syrup Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Syrup Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Forms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Forms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • JAPAN
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • CHINA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: China 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: China 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • EUROPE
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Antitussive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • FRANCE
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: France 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: France 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • GERMANY
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Antitussive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • INDIA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: India 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: India 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Antitussive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Antitussive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Antitussive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030
  • AFRICA
    • Antitussive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Antitussive Drugs by Drug Class - Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Antitussive Drugs by Drug Class - Percentage Breakdown of Value Sales for Peripherally Acting Drugs, Centrally Acting Drugs and Other Drug Classes for the Years 2014, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Antitussive Drugs by Indication - Other Indications, Pain Indication, Cold Indication and Cough Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Antitussive Drugs by Indication - Percentage Breakdown of Value Sales for Other Indications, Pain Indication, Cold Indication and Cough Indication for the Years 2014, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Antitussive Drugs by Form - Tablets Form, Syrup Form and Other Forms Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Antitussive Drugs by Form - Percentage Breakdown of Value Sales for Tablets Form, Syrup Form and Other Forms for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제